While innovative therapies such as ARNIs, SGLT2 inhibitors, and device-based treatments have greatly enhanced outcomes for chronic heart failure, their advantages may not be fully realized in patients experiencing acute cardiogenic shock, which is often characterized by severe decompensation and multi-organ failure. This evidence concerns the gene SLC5A2 and Shock.